Related Experiment Video
Updated: Apr 12, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Beyond "second-line" in non-small cell lung cancer: therapy and supportive care
Renato G Martins1, Craig H Reynolds1, Gregory J Riely1
1From Seattle Cancer Care Alliance, University of Washington, Seattle, WA; US Oncology Research, Ocala, FL; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Abstract:
Although there once was a single algorithm for the treatment of patients with advanced lung cancer, the modern treatment of advanced lung cancer has multiple treatment pathways that depend on multiple factors, including histology and molecular subtype of disease. New molecular targets, targeted agents, and modes of therapy for patients, including immunotherapy, are being identified at an accelerating pace. These advances are changing outcomes and the treatment landscape, but they also highlight situations with inadequate data to support the use of cytotoxic chemotherapy. In this article, we provide an overview of data regarding cytotoxic chemotherapy and targeted therapy and their value after second line, review the critical role of supportive care and palliative care, and emphasize the importance of advance care planning with our patients. Although this article focuses primarily on NSCLC, the comments about palliative care and advanced care planning also apply to patients with small cell lung cancer.
Insights
Modern advanced lung cancer treatment involves diverse pathways based on disease characteristics. This overview covers chemotherapy, targeted therapy, supportive care, and advance care planning for improved patient outcomes.
Area of Science:
- Oncology
- Medical Oncology
Background:
- Treatment for advanced lung cancer has evolved from a single algorithm to multiple pathways.
- Histology and molecular subtype significantly influence treatment decisions.
- Rapid advancements in molecular targets, targeted agents, and immunotherapies are transforming outcomes.
Purpose of the Study:
- To provide an overview of cytotoxic chemotherapy and targeted therapy data for advanced lung cancer.
- To review the role of supportive and palliative care.
- To emphasize the importance of advance care planning in lung cancer management.
Main Methods:
- Review of existing data on cytotoxic chemotherapy and targeted therapy efficacy.
- Discussion of current treatment landscape and emerging therapies.
- Focus on non-small cell lung cancer (NSCLC) with applicability to small cell lung cancer.
Main Results:
- The landscape of advanced lung cancer treatment is complex and rapidly evolving.
- Targeted therapies and immunotherapies are increasingly important.
- Data supporting the use of cytotoxic chemotherapy in certain advanced lung cancer scenarios is limited.
Conclusions:
- Treatment decisions for advanced lung cancer require consideration of histology, molecular subtype, and available therapies.
- Supportive care, palliative care, and advance care planning are crucial components of comprehensive lung cancer management.
- Further research is needed to optimize treatment strategies and supportive care for all lung cancer patients.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:27Tumor Immunotherapy